Using an immunoprecipitation-reverse transcription-PCR technique, we characterized a thymidylate synthase (TS) ribonucleoprotein complex in cultured human colon cancer cells that consists of TS protein and the mRNA of the nuclear oncogene c-myc. TS protein is complexed in intact cells with the C-terminal coding region of c-myc mRNA that includes nucleotide positions 1625 to 1790. RNA electrophoretic gel mobility shift assays confirm a specific interaction between TS protein and c-myc mRNA and provide additional evidence that the C-terminal coding region represents an important cis-acting regulatory element. Further evidence demonstrates that the in vitro translational efficiency of c-myc mRNA is inhibited as a result of its direct interaction with TS protein. In addition, the presence of exogenous c-myc mRNA specifically relieves the inhibitory effects of TS protein on TS mRNA translation.
Efforts to characterize the mechanisms that control gene expression have largely focused on transcriptional events, but recent evidence suggests that posttranscriptional, translational, or posttranslational processes may be important in determining rates of protein synthesis. A number of eukaryotic mRNAs are regulated at the level of translation (14) . For example, the synthesis of proteins involved in iron homeostasis, including ferritin and 5-aminolevulinate synthase, is controlled by an iron-responsive element within the 5Ј untranslated region (UTR) of both ferritin mRNA and 5-aminolevulinate synthase mRNA to which the iron-responsive-element-binding protein binds (13, 20, 25, 32) . This interaction results in the translational inhibition of each of these mRNAs.
Studies from this laboratory have shown that translation of human thymidylate synthase (TS) mRNA is regulated by its own protein product through a negative autoregulatory mechanism (5) . Although translational autoregulation was previously described in both prokaryotic (11, 35 ) and bacteriophage T4 (1, 33, 34) systems, TS represents the first eukaryotic gene product to be regulated in such a manner. The inhibitory effect of TS protein on TS mRNA translation is associated with binding of the protein to two different sequences on its corresponding TS mRNA (8) . The first site includes the translational start site incorporated into a stem-loop structure, while the second site is contained within a 100-nucleotide (nt) sequence of the protein-coding region. In addition to the characterization of this translational regulatory mechanism (8) , in vitro studies have shown that short-term exposure of human H630 colon cancer cells to the chemotherapeutic agent 5-fluorouracil was associated with an increased expression of TS protein resulting from enhanced translation of TS mRNA (6) . Similarly, exposure of human MCF-7 breast cancer cells to the folate analog ZD1694 was associated with a markedly increased level of TS protein expression with no associated change in the level of TS-specific mRNA (19) . In both cases, binding of the inhibitor to TS prevented its regulatory interaction with TS mRNA. These two studies demonstrated that TS protein expression in response to cytotoxic stress was controlled at the translational level and offered evidence for the biological relevance of TS translational autoregulation.
Recently, an immunoprecipitation-reverse transcription (RT)-PCR technique was used to isolate a TS ribonucleoprotein (RNP) complex made up of TS protein and TS RNA in human colon cancer cells (7) . This work demonstrated that this TS RNP complex was not polysome associated and, for the first time, provided evidence for the existence of a TS mRNA-TS protein complex in intact cells. Furthermore, preliminary work revealed that TS protein also formed an RNP complex with the mRNA of the nuclear oncogene c-myc in intact cells.
The purpose of this study is to characterize the specific interaction between TS protein and c-myc RNA. Using both a cell-free RNA electrophoretic mobility shift assay (EMSA) system and an immunoprecipitation-RT-PCR technique, we have identified that TS binding to c-myc mRNA occurs within a sequence that includes the basic region (Br) and helix-loophelix (HLH) motifs. In addition, evidence is presented that suggests a functional role for this RNA-protein interaction in regulating c-myc mRNA translation.
MATERIALS AND METHODS
Cell culture. The characteristics of the human colon cancer cell line H630 and its 5-fluorouracil-resistant H630-R10 subline have been previously described (18, 28) . Cell lines were grown in 75-cm 2 plastic tissue culture flasks (Falcon Labware, Oxnard, Calif.) in growth medium containing RPMI 1640 with 10% dialyzed fetal bovine serum and 2 mM glutamine. Dialyzed fetal bovine serum and all other tissue culture components were obtained from GIBCO (Grand Island, N.Y.).
Whole-cell extraction and immunoprecipitation of RNP complexes. Wholecell extracts were prepared from 1 ϫ 10 8 to 2 ϫ 10 8 cells as previously described (7, 23) . Immunoprecipitation of RNP complexes was performed as described by Steitz (31) . In brief, whole-cell extracts from approximately 3 ϫ 10 7 cells (1.5 to 2.0 mg of total cellular protein) were first cleared of nonspecific binding material by incubation with Immunoprecipitin (300 l; GIBCO BRL, Gaithersburg, Md.) for 30 min on ice and then centrifuged. The cleared extract was then incubated with the appropriate antibody for 30 min to which Immunoprecipitin (300 l), yeast carrier RNA (35 g; U.S. Biochemical, Cleveland, Ohio), and Inhibitase (30 U; 5-Prime-3-Prime, Boulder, Colo.) were added for an additional 30 min. The Immunoprecipitin-immune complex precipitates were centrifuged at 14,000 ϫ g for 3 min and then washed four times with 350 l of NET-2 buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, and 0.05% [vol/vol] Nonidet P-40). After addition of 300 l of NET-2 buffer, the immunoprecipitate pellets were subjected to phenol-chloroform extraction. The RNA fraction of the RNP complex was isolated by ethanol precipitation and then used in the RT reaction.
RT-PCR analysis. The entire immunoprecipitated RNA sample was subjected to RT, using the Stratagene first-strand cDNA protocol (Stratagene, San Diego, Calif.). The RT products were stored at Ϫ20ЊC until further use.
All DNA oligonucleotide primers were synthesized on an Applied Biosystems model 391 DNA synthesizer. Their sequences are as follows (the underlined bases are not part of the target gene sequence and represent unique restriction enzyme digestion sites): c-myc-1, GGCGAACACACAACGTCTTGGAG; c-myc-2, GCTCAGGACATTTCTGTTAGAAG; c-myc-3, CTCGAATTCGAT GCCCCTCAACGT; c-myc-4, CGTCGAGGAGAGCAGAGAA; c-myc-5, GTG GCACCTCTTGAGGACCAG; c-myc-6, TGCTCTCCTCGACGGAGTCCT; cmyc-7, ACCGGATCCCTGAGGACCCCC; c-myc-8, ACCAAGCTTGCTTAC CTGGTT; c-myc-9, ACCAGGAAAAGTAAGGAAAAC; and c-myc-10, ACC TAAAATTTTTTAAAAACA.
The single-stranded cDNA obtained from the RT reaction was then used as template for PCR amplification. The reaction conditions were those outlined by the Perkin-Elmer protocol (Perkin-Elmer Cetus, Emeryville, Calif.), and the total volume of the reaction mixture was 100 l. Mineral oil (40 l) was placed on top of the aqueous solution to prevent evaporation. Reactions were cycled in a Perkin-Elmer Cetus thermal cycler, and samples were incubated at 96ЊC for 1 min, 62ЊC for 1 min, and 72ЊC for 1 min for 35 cycles. At the end of the 35th cycle, the reaction samples were incubated for an additional 10 min at 72ЊC and then cooled to 4ЊC. RT-PCR DNA products were resolved on a 1.5% nondenaturing agarose gel stained with ethidium bromide.
Preparation of plasmid constructs and in vitro mRNA transcription. The full-length TS mRNA transcript was synthesized with SP6 RNA polymerase following linearization of pcEHTS with HindIII (5). The full-length c-myc RNA transcript corresponding to exons 2 and 3 (nt 559 to 2121) was synthesized with SP6 RNA polymerase after linearization of pSp72-c-myc with BglII. The c-mycexon 1 DNA construct was prepared by PCR amplification under standard conditions, using 100 pmol of primers c-myc-6 and c-myc-7 and 0.5 pmol of genomic c-myc DNA. The c-myc-6 primer contained a BamHI restriction site, and the c-myc-7 primer contained a HindIII restriction site. Amplified DNAs were linearized with BamHI and HindIII and then cloned into the BamHI and HindIII sites of pGEM-4Z. The c-myc-exon 1 RNA was synthesized with SP6 RNA polymerase after the corresponding DNA plasmid was linearized with HindIII. The 1,269-bp c-myc/⌬1798-1857 fragment was excised from plasmid pGEX-3X by using the restriction enzymes BamHI and EcoRI and cloned into the BamHI and EcoRI sites of pGEM-4Z (Promega), and pGEM-4Z/c-myc/ ⌬1798-1857 RNA was synthesized with T7 RNA polymerase after linearization with BamHI. The 1,204-bp c-myc/⌬1666-1790 fragment was excised from the plasmid pGEX-3X by using the restriction enzymes BamHI and EcoRI and cloned into the BamHI and EcoRI sites of pGEM-4Z (Promega), and pGEM-4Z/c-myc/⌬1666-1790 RNA was synthesized with T7 RNA polymerase after linearization with BamHI.
In vitro transcription reactions were performed as previously described (5). Labeled RNA transcripts were made by inclusion of [␣ 32 P]CTP at 200 Ci/mmol. All RNA transcripts were evaluated on a 1% agarose-formaldehyde gel to verify their integrity and size. The concentration of unlabeled RNA was determined by UV absorbance spectrophotometry. The concentration of radioactively labeled RNA was determined from the specific activity of 32 P incorporation. RNA-protein binding assay. RNA EMSAs were performed as previously described (8, 22) . In brief, labeled RNAs (2.2 fmol, 100,000 cpm) were incubated with TS protein (3 pmol) in a reaction mixture containing 10 mM N-2-hydroxyethylpiperazine-NЈ-ethanesulfonic acid (HEPES; pH 7.4), 40 mM KCl, 3 mM MgCl 2 , 0.1 U of Inhibitase (5-Prime-3-Prime) per l, and 5% glycerol for 15 min at room temperature. RNase T 1 (5 U; 5-Prime-3-Prime) was then added for 10 min, followed by heparin sulfate (5 mg/ml; Sigma) for an additional 10 min at room temperature. A 4% polyacrylamide gel (acrylamide/methylene bisacrylamide ratio, 60:1) was preelectrophoresed for 30 min at 150 V, and the entire reaction mix (total volume, 30 l) was then resolved on the gel for approximately 40 min at 500 V. The gel was then transferred to Whatman filter paper, dried, and visualized by autoradiography.
Competition experiments were performed with human recombinant TS protein (3 pmol) and either 32 P-labeled TS mRNA (2.2 fmol, 100,000 cpm) or 32 P-labeled c-myc mRNA (2.2 fmol, 100,000 cpm). These conditions were selected on the basis of experiments using a fixed amount of radiolabeled RNA probe with increasing TS protein concentration to determine linearity of binding. Unlabeled competitor RNAs were mixed with labeled probes prior to addition of TS protein. The relative binding affinity (IC 50 ) of unlabeled RNAs represents the concentration of unlabeled RNA at which specific binding of 32 P-labeled fulllength c-myc RNA was inhibited by 50%. Each RNA competition experiment was performed three to six times. Quantitation by densitometry was done with a ScanJet Plus scanner (Hewlett-Packard) and analyzed by using NIH Image 1.36 software (Wayne Rasband, National Institute of Mental Health, Bethesda, Md.).
In vitro translation. Translation reaction mixtures (final volume, 30 l) were prepared with a rabbit reticulocyte protein-processing in vitro translation system (New England Nuclear, Boston, Mass.) as previously described (5) . The translation products were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (12.5% acrylamide) according to the method of Laemmli (21) , and the gels were processed as previously described (5). After drying for 2 h, the translation products were visualized by autoradiography. Quantitation of signal intensities was performed by densitometry on a ScanJet Plus scanner (Hewlett-Packard) and analyzed by using NIH Image 1.36 software (Wayne Rasband, National Institute of Mental Health, Bethesda, Md.).
RESULTS

Previous studies using an immunoprecipitation-RT-PCR
technique demonstrated that TS protein forms an RNP complex with c-myc RNA in intact human colon cancer cells (7) . To determine the specificity of this RNA-protein interaction and to identify the cis-acting elements on c-myc RNA, we performed immunoprecipitation experiments using whole-cell lysates from a human colon cancer cell line (H630-R10). The RNP complexes were immunoprecipitated with TS-specific antibody, and the nucleic acid fraction specifically bound to TS protein was isolated and then subjected to RT-PCR amplification using c-myc-specific primers (Fig. 1B) . As predicted, immunoprecipitation with a TS polyclonal antibody gave rise to a 275-bp DNA fragment (Fig. 1A, lane 1) . Immunoprecipitation with a murine monoclonal antibody to TS yielded a DNA fragment of the same size (data not shown). Prior to RT-PCR amplification, the immunoprecipitated nucleic acid fraction was treated with DNase (Fig. 1A, lane 2) . Under this condition, the 275-bp DNA insert was obtained. In contrast, when the isolated nucleic acid fraction was treated with RNase A prior to RT-PCR amplification (Fig. 1A, lane 3) , the DNA product was not obtained. Similarly, when immunoprecipitated nucleic acids were directly PCR amplified without RT (Fig. 1A,  lane 4) or when whole-cell supernatant extracts were initially deproteinized by phenol-chloroform treatment prior to immunoprecipitation (Fig. 1A, lane 5) , there was no PCR product. To demonstrate the specificity of antibody recognition, either no antibody (Fig. 1A, lane 6) or unrelated antibodies such as preimmune antisera (Fig. 1A, lane 7) or an anti-␣-tubulin mouse monoclonal antibody (Fig. 1A , line 8) were used to immunoprecipitate RNP complexes. Under each of these conditions, amplification of the 275-bp fragment was not observed. These control experiments provide evidence that the nucleic acid of origin for this PCR product was specific for c-myc RNA.
To define the region(s) on c-myc RNA involved in binding to TS protein in human colon cancer cells, various c-myc-specific primers were designed in order to PCR amplify critical regions on c-myc mRNA (Fig. 2C) . We first performed control PCR experiments in which each of these primers was used along with the full-length c-myc cDNA as a template. In each case, the predicted DNA product was observed ( Fig. 2A) . When primer sets representing either the 3Ј UTR (Fig. 2B, lane 3) , the 5Ј UTR (Fig. 2B, lane 4) , or part of the protein-coding region (nt 559 to 1462) (Fig. 2B, lane 2) were used along with immunoprecipitated RNA that was reverse transcribed, no DNA product was PCR amplified. However, using two different c-myc-specific primer sets, one corresponding to nt 1625 to 1900 and another corresponding to nt 1625 to 1790, DNA fragments of 275 bp (Fig. 2B, lane 1) and 165 bp (Fig. 2B , lane 5) were obtained by PCR amplification.
To confirm the specific interaction between c-myc RNA and TS protein in intact cells, an RNA EMSA was used. Full-length radiolabeled c-myc RNA probe was incubated with human recombinant TS protein, resulting in a complex with a slower migration (Fig. 3, lane 2) . However, when TS protein was first treated either with proteinase K (Fig. 3, lane 3) or by heat denaturation (Fig. 3, lane 4) prior to incubation with radiolabeled c-myc RNA probe, no complex was formed. The inability of denatured TS protein to bind to c-myc RNA was also observed in studies examining the interaction between TS protein and its own TS mRNA (8) . This observation lends further evidence that the native state of TS protein appears to be an important determinant for its RNA binding properties. No complex was formed when radiolabeled c-myc RNA probe was incubated with unrelated proteins such as bovine serum albumin (Fig. 3, lane 5) or a glutathione S-transferase-Max fusion protein (Fig. 3, lane 6) , lending further support for the specificity of this particular RNA-protein interaction. Of interest, in vitro-translated c-Myc protein did not bind to radiolabeled c-myc RNA (data not shown).
In an attempt to localize more precisely the sites on c-myc RNA directly involved in protein binding, competition EMSAs were performed. In each reaction mix, radiolabeled full-length c-myc RNA and human recombinant TS protein were incubated together, along with a molar excess of unlabeled RNA competitor. As seen in Fig. 4A , when a 5-to 100-fold molar excess of either unlabeled full-length TS RNA or c-myc RNA was included in the reaction mix, complex formation was inhibited to essentially the same degree, suggesting that their relative binding affinities to TS protein were similar (IC 50 ϭ 1.0 and 1.2 nM, respectively) (Fig. 4A) . In contrast, the addition of unlabeled full-length antisense c-myc RNA did not inhibit complex formation, even when concentrations of up to 100-fold molar excess were used (Fig. 4A) .
Given the results presented in Fig. 1 and 2 that identified a 275-nt c-myc RNA sequence, a region containing the Br-HLHleucine zipper (LZ) motifs, c-myc RNA sequences with various deletions in this region were synthesized in vitro (Fig. 4D) . As shown previously, unlabeled c-myc RNA effectively blocked complex formation when used in 10-to 100-fold molar excess (Fig. 4B) . With the inclusion of an unlabeled c-myc RNA sequence with a 60-nt (nt 1798 to 1857) deletion in the region encoding for the LZ motif, the formation of complex was inhibited to the same extent as observed for full-length wildtype c-myc RNA (IC 50 ϭ 1.2 nM; Fig. 4B ). In contrast, complex formation was maintained when a c-myc RNA sequence VOL. 15, 1995 BINDING OF THYMIDYLATE SYNTHASE TO c-myc RNA 181
with a 124-nt deletion (nt 1666 to 1790) in the region that includes the Br and HLH motifs. These findings suggested that the region containing the LZ sequence was not necessary, while the region containing the Br and HLH sequence was required for binding. To examine this possibility more specifically, a 70-nt c-myc RNA sequence specific for the HLH-encoding region (nt 1720 to 1790) was synthesized in vitro. This sequence was unable to compete for protein binding even when a concentration of up to 100-fold molar excess was used ( Fig. 4C; Table 1 ). A 40-nt RNA transcript corresponding to the Br-encoding sequence also did not inhibit complex formation (Table 1) . Similarly, a 70-nt sequence specific for the region encoding for the LZ motif (nt 1790 to 1860) was unable to bind to TS protein ( Fig. 4C ; Table  1 ). However, a 275-nt sequence corresponding to nt 1625 to 1900 and a 165-nt sequence corresponding to nt 1625 to 1790 were both able to bind TS protein to a degree similar to that observed with the full-length wild-type c-myc RNA (IC 50 ϭ 2.0 and 1.7 nM, respectively; Fig. 4C ). These results combined with those from the RT-PCR analyses suggest that binding to c-myc RNA occurs between nt 1625 and 1790.
To begin to address the functional role of the interaction between TS protein and c-myc RNA, a series of in vitro translation experiments was performed. Translation of rabbit lysate in the absence of exogenous mRNA gives rise to a protein product with a molecular mass of 47 kDa. This protein is present in all of the in vitro translation reactions ( Fig. 5 and 6 ). TS mRNA and c-myc mRNA, at two different amounts, 2 (Fig.  5A, lane 1) and 4 (Fig. 5A, lane 2) pmol, were incubated together in the same reaction mix. Their corresponding protein products resolved at molecular masses of 35 kDa (TS) and 62 kDa (c-Myc). In the presence of exogenous TS protein, significant inhibition of TS mRNA translation was observed (Fig.  5A , lane 4) similar to that previously described (5) . As determined by our in vitro competition experiments (Fig. 4A) , both TS RNA and c-myc RNA bind TS protein with the same relative affinity. Given the competitive relationship between a Binding of TS protein to various c-myc RNAs relative to full-length c-myc RNA was determined by comparing the concentration of RNA at which specific binding of 32 P-radiolabeled full-length c-myc RNA was inhibited by 50%. Each value represents the mean Ϯ standard error of three to six experiments. these two RNA transcripts, we determined whether the presence of excess c-myc RNA in a rabbit lysate containing TS RNA and TS protein might abrogate the translational inhibitory effects of TS protein. As shown in Fig. 5A , in the presence of excess c-myc mRNA, the inhibitory effect of TS protein on TS mRNA translation was repressed in a dose-dependent manner, returning the translational efficiency of TS mRNA to control levels (Fig. 5A, lanes 5 and 6) . Comparison of the translational efficiencies of c-myc mRNA in the absence (Fig.  5A, lanes 1 and 2) and presence (Fig. 5A, lanes 5 and 6) of TS protein revealed nearly complete inhibition by TS protein on the synthesis of c-Myc protein. This inhibitory effect of TS protein on c-myc mRNA translation was confirmed when only c-myc mRNA was incubated in the presence of exogenous TS protein (Fig. 5B, lane 2) . Furthermore, this interaction did not result in the synthesis of truncated c-Myc protein products, a finding that suggests that binding of TS was associated with the inhibition of translational initiation of c-myc RNA.
The effect of c-myc-truncated RNA sequences on TS translational autoregulation was subsequently examined. TS mRNA translation was completely inhibited in the presence of human TS protein (Fig. 6A, lane 2) . When either a 10-or 20-fold molar excess of c-myc/1625-1790 RNA (Fig. 6A, lanes 3 and 4) or full-length c-myc mRNA (Fig. 6A, lanes 5 and 6) was included in rabbit lysate reactions containing both TS mRNA and TS protein, translation of TS mRNA was restored to control levels (Fig. 6A, lane 1) . The translational inhibitory effects of TS protein (Fig. 6B, lane 2) were not abrogated in the presence of either excess full-length antisense c-myc RNA (Fig. 6B, lane 3) , c-myc/1790-1860 RNA (Fig. 6B, lane 4) , or poly(I-C) (Fig. 6B, lane 5) . These experimental findings further support the specificity of the interaction between c-myc RNA and TS protein.
DISCUSSION
In this work, we used an immunoprecipitation-RT-PCR technique to demonstrate that TS protein forms an RNP complex in human colon cancer cells with the RNA of the nuclear oncogene c-myc. Our experiments demonstrate that in actively growing human colon cancer cells, TS binds to a single 275-nt sequence located in the C-terminal protein-coding region of c-myc RNA. No other sequences on c-myc RNA were observed to interact with TS to form a TS RNP complex, including the regions that correspond to the 5Ј and 3Ј UTRs. The fact that we were able to immunoprecipitate only one c-myc RNA sequence suggests that c-myc RNA is subject to RNase digestion during the immunoprecipitation-RT-PCR procedure and that only the sequence directly complexed with TS remains protected from degradation. In support of this possibility are recent studies in which an anti-c-myc antibody was used to immunoprecipitate polysome-associated c-myc RNP complexes (7). Presumably, this RNP complex would consist of nascent polypeptide chains associated with full-length c-myc RNA. However, even with the use of an anti-c-myc antibody, we were unable to RT-PCR amplify the complete c-myc RNA sequence, suggesting that degradation of the RNA was taking place during the immunoprecipitation procedure. The presence of complex secondary structure along regions of c-myc RNA is another technical factor that might make RT-PCR amplification of other RNA sequences especially difficult. To address this issue, control RT-PCRs were performed with either in vitro-synthesized c-myc RNA or total cellular RNA extracted from the H630-R10 cell line as the starting material. In each case, the appropriate c-myc DNA products were amplified, as observed in the control experiments presented in Fig. 2A . While this observation would appear to rule out the role of secondary structure in our inability to RT-PCR amplify other c-myc RNA sequences, our studies remain limited in that they do not account for the potential effects of protein binding on altering the secondary structure of its target RNA.
To further define the cis-acting element(s) involved in protein binding, we performed an RNA EMSA. Using various c-myc RNA sequences in competition experiments, we identified a 165-nt sequence corresponding to nt 1625 to 1790 of c-myc mRNA as an important cis-acting element for protein binding. The relative binding affinity of TS for this truncated c-myc RNA sequence is nearly identical to that observed with the full-length c-myc mRNA. While this region on c-myc mRNA includes the sequence encoding for the Br and HLH regulatory elements, it is apparent that RNA sequences specific for only the Br and/or HLH motifs are unable to interact with TS (Fig. 4C) . Moreover, a c-myc mRNA sequence with a deletion in the region encoding for the LZ motif was still able to bind TS protein, eliminating this part of the C-terminal coding region as being required for protein binding. Direct comparison of the data obtained from either the intact-cell immunoprecipitation-RT-PCR analysis or the cell-free EMSA reveals identical localization of the cis-acting site on c-myc mRNA. Previous investigations also showed that the cis-acting sequences on TS mRNA for TS protein could be identified with either the cell-free or intact-cell technique (8) .
In addition to its normal enzymatic function of maintaining VOL. 15, 1995 BINDING OF THYMIDYLATE SYNTHASE TO c-myc RNA 183 the proper level of precursor deoxynucleotides for DNA biosynthesis (9, 12, 30) , recent studies have shown that TS protein controls the translation of its own mRNA in an autoregulatory manner (5, 7, 8) . TS protein binds to two distinct sites on its corresponding mRNA, thereby inhibiting TS mRNA translation (8) . Since TS protein binds to both TS mRNA and c-myc mRNA with nearly identical affinity, we determined whether the presence of excess c-myc RNA could alter the translational autoregulatory effects of TS protein. Using a rabbit reticulocyte lysate in vitro translation system, we found that the addition of exogenous full-length c-myc RNA completely repressed the inhibition of TS mRNA translation by TS protein. Moreover, the c-myc RNA sequence corresponding to nt 1625 to 1790 that was identified as an important cis-acting element was also able to effectively repress TS translational autoregulation. This effect was specific since the addition of other c-myc RNAs such as full-length antisense or the sequence encoding the LZ motif was unable to relieve the translational inhibition by TS protein. Furthermore, upon its binding to TS protein, the translational efficiency of c-myc mRNA was dramatically reduced in a manner similar to that observed with the TS mRNA-TS protein interaction. These results suggest that the interaction between TS protein and c-myc RNA may serve a dual biological role depending on their relative stoichiometry within a given cell. When c-myc RNA is present in excess, it can disrupt the normal translational autoregulatory function of TS, resulting in an increased synthesis of new TS protein. However, when the intracellular level of TS protein is sufficient to allow for ongoing cellular growth and function, TS is then free to bind both to its own corresponding TS mRNA and to c-myc mRNA, resulting in their translational inhibition. This model may begin to explain the findings observed in various in vitro studies investigating the cell cycle regulation of c-myc and TS. In the resting state, the levels of c-myc RNA and c-Myc protein are barely detectable (3, 10, 24) . However, as cells are stimulated to enter the G 1 phase of the cell cycle, the levels of c-myc expression are markedly increased and then decline upon entry into the S phase. While TS expression is also increased with the proliferative state of the cell, in contrast to c-myc, its induction occurs in the S phase of the cell cycle (2, 4, 6, 17, 26) . In our proposed model, high levels of c-myc RNA that arise as growth-stimulated cells enter the G 1 phase could bind to free intracellular TS protein. The net effect of this interaction would be to limit the normal regulatory function of TS protein to inhibit its own translation, leading to an increased expression of newly synthesized TS. As the requirements for DNA biosynthesis are met during the late stages of S phase, any excess free TS protein within the cell would then be able to bind to its own TS mRNA and to c-myc RNA, resulting in decreased translational efficiency. Thus, it appears that our experimental findings may have biological relevance in that they suggest a mechanism by which the cellular requirements for c-Myc and TS protein are met. Further studies are required, however, to determine whether the translational regulation of c-myc RNA by TS protein occurs in an intact cellular system. An important issue raised by this study relates to how binding of TS to a sequence in the C-terminal region of c-myc mRNA is associated with translational inhibition. This finding suggests that the c-myc RNA-TS protein interaction either interferes with binding of the translational machinery composed of ribosomes and translation initiation factors near or at the cap site or interferes directly with ribosomal scanning. However, for such regulatory events to occur, some type of interactive cross-talk between the 5Ј end and the C-terminal region is required. In support of this are recent observations that identified sequences within the 3Ј UTR involved in the translational regulation of various mRNAs (15, 16, 27) . Although there is now a growing body of evidence demonstrating the ability of RNA-protein interactions in the 3Ј UTR to affect translational initiation, the precise molecular mechanisms by which this takes place remain to be characterized.
Recent studies have identified a coding-region determinant (CRD)-binding protein that binds to the C-terminal coding region (CRD) of human c-myc mRNA (29) . While the precise biological significance of this specific RNA-protein interaction remains to be determined, it has been suggested that this CRD-binding protein may, in part, affect the stability of c-myc mRNA. Comparison of the CRD and the c-myc RNA binding sequence identified in this report reveals that both are located in the C-terminal coding region and overlap one another by 85 nt. The ability of this c-myc RNA target sequence to interact with two apparently different RNA-binding proteins further emphasizes its critical role in the posttranscriptional regulation of c-myc expression.
In conclusion, our studies demonstrate that in addition to its role in the regulation of TS mRNA translation, TS protein may be involved in the translational regulation of c-myc mRNA. Preliminary studies from this laboratory have also revealed an interaction between TS protein and L-myc mRNA, another member of the myc family of oncogenes. While our studies suggest that the cis-acting elements on L-myc, c-myc, and TS mRNA are distinct from one another, additional work is ongoing in an effort to identify a consensus TS-responsive sequence(s) and/or secondary structure(s) that is involved in the regulation of expression of these genes. However, the studies presented herein expand our current understanding of the critical regulatory function of TS protein in determining cellular gene expression.
